title: Evaluation of 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) as an ex vivo bacterial detection agent.
abstract: The nucleoside analogue, 1-(2-deoxy-2-fluoro-1-D-arabinofuranosyl)-5-iodouracil (FIAU) is a substrate for thymidine kinase (TK), which is commonly expressed in bacteria. It is currently being investigated in clinical studies as an in vivo bacterial infection detection agent. In developing countries where imaging facilities are not readily available, deploying such technology can be a big hurdle. However, a portable ex vivo system might provide a good alternative. In an in vitro system, [(125)I]-FIAU incubated with bacteria is phosphorylated by TK, and is trapped within the bacteria, which can be detected by radioscintography. The suitability of this agent to be utilized as part of an ex vivo bacterial detection system was evaluated. In the first part of this report, the optimization of the incubation and detection condition using E. coli as a test case is described. Samples were incubated in a growth promoting medium containing the label, then after filtering and washing, the amount of radioactivity trapped on the filter was quantitated by a scintillation counter. As a proof of concept demonstration, blinded urine samples from urinary tract infection (UTI) patients and normal donors were tested in the FIAU system. Of the 13 UTI positive and 15 normal urine samples tested, there were 2 false negatives and 1 false positive, respectively. Potential explanations for the false positive and negatives as well as the commercialization possibility of this system will be discussed.
authors.affiliation: BioMed Valley Discoveries, 16th Floor, 4520 Main Street, Suite 1650, Kansas City, MO, 6411, USA, dtung@biomed-valley.com.
authors.forename: David
authors.initials: D
authors.lastname: Tung
authors.forename: Gary
authors.initials: G
authors.lastname: DeCrescenzo
authors.forename: Dean
authors.initials: D
authors.lastname: Welsch
authors.forename: Peter H
authors.initials: PH
authors.lastname: Cheung
authors.forename: Chetan
authors.initials: C
authors.lastname: Bettegowda
authors.forename: Saurabh
authors.initials: S
authors.lastname: Saha
mesh_terms: D001086:Arabinofuranosyluracil / Q000031:analogs & derivatives* / Q000378:metabolism; D001419:Bacteria / Q000302:isolation & purification* / Q000378:metabolism; D001424:Bacterial Infections / Q000175:diagnosis* / Q000382:microbiology; D001431:Bacteriological Techniques / Q000379:methods*; D003951:Diagnostic Errors; D006801:Humans; D019095:Point-of-Care Systems; D011874:Radiometry / Q000379:methods*; D014552:Urinary Tract Infections / Q000175:diagnosis; D014556:Urine / Q000382:microbiology
chemical_list: D001086:Arabinofuranosyluracil; C043457:fialuridine
references.citation: J Clin Microbiol. 1999 Sep;37(9):3051-2
references.pmid: 10449505
references.citation: Lancet Infect Dis. 2003 Apr;3(4):223-9
references.pmid: 12679265
references.citation: J Clin Microbiol. 1985 May;21(5):840-2
references.pmid: 3998118
references.citation: PLoS One. 2007 Oct 10;2(10):e1007
references.pmid: 17925855
references.citation: Cancer Res. 1995 Dec 15;55(24):6126-32
references.pmid: 8521403
references.citation: Am J Nucl Med Mol Imaging. 2012;2(3):260-70
references.pmid: 23133816
references.citation: J Clin Microbiol. 1983 Nov;18(5):1256-7
references.pmid: 6358253
references.citation: Proc Natl Acad Sci U S A. 2005 Jan 25;102(4):1145-50
references.pmid: 15653773
references.citation: Cell Mol Life Sci. 2002 Aug;59(8):1327-46
references.pmid: 12363036
references.citation: Clin Microbiol Infect. 2010 Aug;16(8):1054-61
references.pmid: 20670287
references.citation: Eur J Nucl Med. 2001 Feb;28(2):241-52
references.pmid: 11303896
references.citation: J Nucl Med. 2002 Aug;43(8):1072-83
references.pmid: 12163634
references.citation: Eur J Nucl Med Mol Imaging. 2009 Dec;36(12):1987-93
references.pmid: 19506865
references.citation: Int J Med Microbiol. 2012 Mar;302(2):101-7
references.pmid: 22264560